CPIX Cumberland Pharmaceuticals
- 1.530
- -0.050-3.16%
Cumberland Pharmaceuticals News
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024...
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Global MRSA Drugs Market Research Report 2023-2032 Featuring AbbVie, Basilea Pharmaceutica, Crystal Genomics, Cumberland Pharmaceuticals, Melinta Therapeutics, Paratek Pharmaceuticals, and Pfizer
DUBLIN, March 28, 2024 /PRNewswire/ -- The "MRSA Drugs Market by MRSA Type, Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2024-2032" report has been added
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript
Cumberland Pharmaceuticals Full Year 2023 Earnings: US$0.44 Loss per Share (Vs US$0.38 Loss in FY 2022)
Earnings Call Summary | Cumberland Pharmaceuticals(CPIX.US) Q4 2023 Earnings Conference
The following is a summary of the Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript:Financial Performance:Cumberland Pharmaceuticals reported Q4 net revenue of $9.4 million, obse
Cumberland Pharma 4Q Rev $9.35M >CPIX
Cumberland Pharma 4Q Rev $9.35M >CPIX
Cumberland Pharmaceuticals Q4 2023 Adj. EPS $(0.11) Down From $(0.05) YoY; Revenue $9.353M Up From $9.123M Est.
Cumberland Pharmaceuticals Q4 2023 Adj. EPS $(0.11) Down From $(0.05) YoY; Revenue $9.353M Up From $9.123M Est.
Press Release: Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire NASHVILLE, Tenn., March 5, 2024 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Ten
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings
Marijuana Reclassification And DEA: Congressional Report Outlines Rescheduling Limits
The U.S. Drug Enforcement Administration (DEA) might finally budge on it is decades-long cannabis criminalization, but don't hold your breath for legal weed shops just yet.
Cumberland Pharmaceuticals Files for $100M Mixed Shelf
Cumberland Pharmaceuticals Non-GAAP EPS of $0.02, Revenue of $10.1M
Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.02
04:11 PM EST, 11/07/2023 (MT Newswires) -- Earnings Flash (CPIX) CUMBERLAND PHARMACEUTICALS Reports Q3 EPS $0.02
Press Release: Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results PR Newswire NASHVILLE, Tenn., Nov. 7, 2023 NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NA
Cumberland Pharma 3Q Loss/Shr 7c >CPIX
Cumberland Pharma 3Q Loss/Shr 7c >CPIX
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. • Ballard Power Systems (NASDAQ:BLDP) is expected to report quarterly loss at
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023...
NEW VIBATV PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
NASHVILLE, Tenn., Oct. 10, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study
,EVA, GRTS and SLGL Are Among Mid-day Movers
Analysis
Price Target
No Data
